Recent price action for Sarepta Therapeutics
Sarepta Therapeutics (SRPT) has drawn attention after a sharp move in its share price, prompting investors to reassess how the stock’s recent trading performance lines up against its fundamentals and longer term returns.
The recent surge in Sarepta Therapeutics’ share price, including a 40.3% 1-month share price return and 46.0% 3-month share price return, points to building momentum. However, the 3-year total shareholder return is down 81.2% and the 5-year total shareholder return is down 71.4%.
Compare Sarepta Therapeutics' sharp move with other stocks gaining traction in this market by scanning our hand picked 21 high quality undiscovered gems.
The sharp rebound in Sarepta Therapeutics after years of weak long term returns raises a simple tension: Has the recent move already captured most of the opportunity, or is the market still underpricing what you are buying at today’s level?
Most Popular Narrative: 6% Overvalued
The most followed narrative puts Sarepta Therapeutics’ fair value at $21.65 per share, slightly below the last close of $22.99. This sets up a cautious valuation gap.
The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.
Want to understand why this narrative still supports a fair value close to today’s price even with forecast revenue contraction and margin shifts? The answer lies in how earnings are expected to move from losses to profits, and in the richer future earnings multiple reflected in the model.
Result: Fair Value of $21.65 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Sarepta Therapeutics still faces meaningful risks, including renewed scrutiny of ELEVIDYS safety and potential delays or setbacks in key gene therapy and siRNA trials.
Find out about the key risks to this Sarepta Therapeutics narrative.
Another View: SWS DCF Versus Analyst Targets
The analyst consensus suggests Sarepta Therapeutics is about 6% overvalued at a fair value of $21.65 per share. Our DCF model presents a very different perspective. It points to a future cash flow value of $628.90 per share, which is far above the current $22.99 price. Which framework do you consider more useful for your own expectations?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sarepta Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals around Sarepta Therapeutics, it helps to move quickly and weigh the facts for yourself before sentiment shifts again. To begin, review the balance of potential upside and downside in our breakdown of 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Sarepta Therapeutics?
Do not stop your research with Sarepta Therapeutics. Broaden your watchlist now so you are not relying on a single story when the next opportunity appears.
- Target steadier compounding potential by reviewing companies in the 79 resilient stocks with low risk scores that may better match your appetite for smaller portfolio swings.
- Strengthen your core holdings by scanning the list of solid balance sheet and fundamentals (53 results) to find businesses with financial profiles that can help underpin long term confidence.
- Pursue value focused ideas by checking the 52 high quality undervalued stocks that highlight companies combining quality fundamentals with prices that may not fully reflect them yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com